On May 30, 2025, the U.S. Food and Drug Administration (FDA) approved Moderna’s next-generation COVID-19 vaccine, mNEXSPIKE (mRNA-1283), for adults aged 65 and older and individuals aged 12 to 64 with underlying health conditions that increase the risk of severe COVID-19, such as chronic illnesses or Long COVID.
This new low-dose vaccine is designed to protect against current virus variants and is expected to be available for the 2025–2026 respiratory virus season.
However, the approval has sparked discussions due to the absence of placebo-controlled trials, raising questions about safety and transparency.
The FDA’s decision was based on a Phase 3 clinical trial involving approximately 11,400 participants aged 12 and older. The trial compared mNEXSPIKE to Moderna’s earlier vaccine, Spikevax (mRNA-1273), rather than a placebo. Results showed mNEXSPIKE had a 9.3% higher efficacy against COVID-19 in those aged 12 and up, with a 13.5% increase in adults 65 and older.
The safety profile was similar to Spikevax, with fewer local reactions reported. Moderna claims mNEXSPIKE offers improved protection and a lower dose, potentially reducing side effects.
Critics, however, argue that the lack of a placebo-controlled trial—a study where some participants receive an inert substance to compare against the vaccine—raises concerns.
So the vaccine has not been studied as thourally compared to previous vaccines.
In May 2025, the FDA updated its guidelines to allow active-controlled trials, like the one used for mNEXSPIKE, instead of mandating placebo studies.
This shift has drawn scrutiny, especially after reports suggested the Department of Health and Human Services (HHS) promised placebo-controlled trials for all new vaccines.
No such mandate appears in current FDA guidelines, but the change has fueled skepticism among those wary of rapid vaccine approvals.
Public sentiment, shows mixed reactions. Some users hailed mNEXSPIKE as a tool for high-risk groups, while others criticized the approval as rushed, citing concerns about untested long-term effects.
Moderna has stated that additional studies, potentially including placebo-controlled trials, may follow, but no specific timeline has been confirmed.
The approval marks Moderna’s third COVID-19 vaccine product and underscores ongoing efforts to adapt to evolving virus strains.
For now, mNEXSPIKE will join Spikevax as an option this fall. As debates over vaccine safety continue, experts urge the public to stay informed and consult healthcare providers.
For more details, visit the FDA’s approval letter (https://www.fda.gov) or Moderna’s official announcement (https://investors.modernatx.com).
Are you planning on receiving the new vaccine. Comment below.
Leave a Reply